Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study

被引：0
|
作者：
Aziz Zaanan
Juliette Palle
Emilie Soularue
Florence Leroy
Samy Louafi
David Tougeron
Sylvain Manfredi
Pascal Artru
Astrid Pozet
Julien Taieb
机构：
[1] European Georges Pompidou Hospital,Department of Gastroenterology and Digestive Oncology
[2] Assistance Publique-Hôpitaux de Paris,Department of Medical Oncology
[3] Paris Descartes University,Department of Gastroenterology and Digestive Oncology
[4] Sorbonne Paris Cité,Department of Cancer Medicine
[5] Saint Antoine Hospital,Department of Oncology
[6] Assistance Publique-Hôpitaux de Paris,Department of Gastroenterology
[7] Saint-Louis Hospital,Department of Gastroenterology and Digestive Oncology
[8] Assistance Publique-Hôpitaux de Paris,Department of Gastroenterology and Digestive Oncology
[9] Gustave Roussy Institute,Methodology and Quality of Life in Oncology Unit, INSERM UMR 1098
[10] Oncology Federation of Essonne,undefined
[11] Poitiers University Hospital,undefined
[12] Rennes University Hospital,undefined
[13] Jean Mermoz Hospital,undefined
[14] Besançon University Hospital,undefined
来源：
Targeted Oncology | 2018年 / 13卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：107 / 112
页数：5
相关论文
共 50 条
  • [41] The safety and efficacy of ramucirumab in combination with paclitaxel for the treatment of advanced gastric or gastro-esophageal junction adenocarcinoma
    Garrido, Marcelo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (10) : 1005 - 1010
  • [42] Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: A multicenter retrospective study (ROSET-BM study)
    Yamanaka, Takashi
    Niikura, Naoki
    Nomura, Hironori
    Kusama, Hiroki
    Yamamoto, Mitsugu
    Matsuura, Kazuo
    Inoue, Kenichi
    Takahara, Sachiko
    Kita, Shosuke
    Yamaguchi, Miki
    Aruga, Tomoyuki
    Shibata, Nobuhiro
    Shimomura, Akihiko
    Ozaki, Yuri
    Shiraishi, Kazuhiro
    Sakai, Shuji
    Kiga, Yoko
    Izutani, Tadahiro
    Shiosakai, Kazuhito
    Tsurutani, Junji
    CANCER RESEARCH, 2023, 83 (05)
  • [43] Efficacy and Safety of Trastuzumab in Combination with S-1 and Cisplatin Therapy for Japanese Patients with HER2-Positive Advanced Gastric Cancer: Retrospective Analysis
    Okita, Akira
    Imai, Hiroo
    Takahashi, Masahiro
    Takahashi, Hidekazu
    Umegaki, Sho
    Kawamura, Yoshifumi
    Hiraide, Sakura
    Ouchi, Kota
    Sato, Yuko
    Okada, Yoshinari
    Komine, Keigo
    Saijo, Ken
    Takahashi, Shin
    Takahashi, Masanobu
    Shirota, Hidekazu
    Ohori, Hisatsugu
    Gamoh, Makio
    Ishioka, Chikashi
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2018, 245 (02): : 123 - 129
  • [44] PD-L1 as a predictive biomarker for pembrolizumab in HER2-positive gastric or gastro-esophageal junction adenocarcinoma-a commentary on KEYNOTE-811
    Yu, James
    Saeed, Anwaar
    CHINESE CLINICAL ONCOLOGY, 2024, 13 (04)
  • [45] Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma
    Porth, Isabel
    Hirsch, Daniela
    Ceribas, Yonca
    Weidner, Philip
    Weichert, Wilko
    Goetze, Thorsten Oliver
    Perner, Sven
    Luley, Kim
    Heyer, Christian Moritz
    de la Torre, Carolina
    Hofheinz, Ralf-Dieter
    Lorenzen, Sylvie
    Gaiser, Timo
    EUROPEAN JOURNAL OF CANCER, 2023, 183 : 119 - 130
  • [46] Combination of pyrotinib with trastuzumab, taxanes and platinum as neoadjuvant therapy in patients with HER2-positive early or locally advanced breast cancer: a multicenter phase II trial
    Zhou, Hao
    Wang, Lei
    Wang, Lei
    Guo, Zhaoji
    CANCER RESEARCH, 2023, 83 (05)
  • [47] Neoadjuvant Chemotherapy with or without Anthracyclines Combined with Trastuzumab and Pertuzumab in HER2-Positive Breast Cancer: A Multicenter Retrospective Study in China
    Zhang, Y.
    Zhou, J.
    Yang, S.
    Li, G.
    Wang, X.
    Bai, L.
    Zhang, S.
    Cao, W.
    Ouyang, T.
    Jiang, Z.
    He, Y.
    Wang, T.
    Fan, Z.
    BREAST, 2025, 80
  • [48] Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
    Park, Ji Soo
    Youn, Jong-Chan
    Shim, Chi Young
    Hong, Geu-Ru
    Lee, Choong-Kun
    Kim, Jee Hyung
    Park, Hyung Soon
    Heo, Su Jin
    Beom, Seung Hoon
    Kim, Hyo Song
    Rha, Sun Young
    Chung, Hyun Cheol
    Kang, Seok-Min
    Jung, Minkyu
    ONCOTARGET, 2017, 8 (37) : 61837 - 61845
  • [49] HER-FLOT: Trastuzumab in combination with FLOT as perioperative treatment for patients with HER2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the AIO Gastric Cancer Study Group.
    Hofheinz, Ralf
    Hegewisch-Becker, Susanna
    Thuss-Patience, Peter C.
    Kunzmann, Volker
    Fuchs, Martin
    Graeven, Ullrich
    Homann, Nils
    Heinemann, Volker
    Pohl, Michael
    Tannapfel, Andrea
    Al-Batran, Salah-Eddin
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [50] Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: a retrospective analysis
    Collova, Elena
    Ferzi, Antonella
    Scandurra, Giuseppa
    Aurilio, Gaetano
    Torri, Valter
    Porcu, Luca
    Sano, Maria Vita
    Taibi, Eleonora
    Foglietta, Jennifer
    Generali, Daniele
    Andreis, Daniele
    Dazzani, Maria Chiara
    Bramati, Annalisa
    Marcon, Ilaria
    Atzori, Francesco
    Cinieri, Saverio
    Tondulli, Luca
    Grasso, Donatalla
    Nole, Franco
    Petrella, Maria Cristina
    Gori, Stefania
    La Verde, Nicla
    TUMORI, 2014, 100 (04) : 426 - 431
12345